PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.10%
Revenue growth 1.25-1.5x ADI's 5.16%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
6.17%
Gross profit growth 1.25-1.5x ADI's 4.44%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
15.50%
EBIT growth above 1.5x ADI's 6.53%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
15.25%
Operating income growth above 1.5x ADI's 6.53%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
14.66%
Net income growth above 1.5x ADI's 5.43%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
16.67%
EPS growth above 1.5x ADI's 4.55%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
16.92%
Diluted EPS growth above 1.5x ADI's 4.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-1.40%
Share reduction while ADI is at 0.39%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.52%
Reduced diluted shares while ADI is at 0.36%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.30%
Dividend reduction while ADI stands at 0.11%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
71.83%
Positive OCF growth while ADI is negative. John Neff would see this as a clear operational advantage vs. the competitor.
82.73%
Positive FCF growth while ADI is negative. John Neff would see a strong competitive edge in net cash generation.
52.13%
10Y revenue/share CAGR at 50-75% of ADI's 75.21%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
6.46%
5Y revenue/share CAGR under 50% of ADI's 13.81%. Michael Burry would suspect a significant competitive gap or product weakness.
12.10%
3Y revenue/share CAGR at 50-75% of ADI's 20.19%. Martin Whitman would question if the firm lags behind competitor innovations.
48.23%
10Y OCF/share CAGR above 1.5x ADI's 29.23%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
24.14%
Positive OCF/share growth while ADI is negative. John Neff might see a comparative advantage in operational cash viability.
29.91%
3Y OCF/share CAGR at 75-90% of ADI's 36.12%. Bill Ackman would press for improvements in margin or overhead to catch up.
101.43%
Similar net income/share CAGR to ADI's 110.75%. Walter Schloss would see parallel tailwinds or expansions for both firms.
7.87%
5Y net income/share CAGR above 1.5x ADI's 3.04%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
12.80%
3Y net income/share CAGR 50-75% of ADI's 21.24%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
33.75%
10Y equity/share CAGR at 50-75% of ADI's 56.12%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
16.21%
Below 50% of ADI's 58.52%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-3.10%
Negative 3Y equity/share growth while ADI is at 19.55%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
2216987.49%
10Y dividend/share CAGR above 1.5x ADI's 300.57%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
182.59%
5Y dividend/share CAGR above 1.5x ADI's 80.70%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
98.80%
3Y dividend/share CAGR above 1.5x ADI's 33.32%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
3.28%
AR growth is negative/stable vs. ADI's 10.53%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-6.05%
Inventory is declining while ADI stands at 7.60%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.66%
Negative asset growth while ADI invests at 1.22%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.92%
We have a declining book value while ADI shows 1.64%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-15.40%
We’re deleveraging while ADI stands at 0.02%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-1.25%
Our R&D shrinks while ADI invests at 4.25%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.66%
We cut SG&A while ADI invests at 2.27%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.